Complete report $1,850. Individual company assessments $250. The companies analyzed in this report include BASF, Cambrex, Clariant, DowPharma, DSM, Evonik, Lanxess, Lonza, Novasep, and Rhodia. For each company, the report presents: • Internally developed and acquired technologies, and related capabilities. • Proprietary technologies and patent litigations. Contains 35 pages
|